BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Timothy L. Jackson, PhD, MBChB, discusses phase 2b trial results of sozinibercept for neovascular age-related macular degeneration.
Sozinibercept (Opthea) targets VEGF-C and VEGF-D and is meant to be used in combination with the VEGF-A-suppressing drugs ranibizumab or aflibercept. In the trial, two different doses of sozinibercept were used in combination with ranibizumab and showed superior efficacy with the higher dose as compared with ranibizumab monotherapy.
“It was exciting to see a drug that was